Skip to main content
SpringerLink
Log in

Prophylactic, empirical, pre-emptive and targeted antibacterial therapy all play a role in invasive aspergillosis

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

References

  1. Krishnan-Natesan S, Chandrasekar PH. Current and future therapeutic options in the management of invasive aspergillosis. Drugs 2008; 68(3): 265–82

    Article  PubMed  CAS  Google Scholar 

  2. Ruping MJGT, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs 2008; 68(14): 1941–62

    Article  PubMed  Google Scholar 

  3. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67(11): 1567–1601

    Article  PubMed  CAS  Google Scholar 

  4. Hasan RA, Abuhammour, W. Invasive aspergillosis in children with hematologic malignancies. Pediatr Drugs 2006; 8(1): 15–24

    Article  Google Scholar 

  5. Stynen D, Goris A, Sarfati J, et al. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995; 33(2): 497–500

    PubMed  CAS  Google Scholar 

  6. Salonen J, Lehtonen OP, Terasjarvi MR, et al. Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. Scand J Infect Dis; 2000; 32(5): 485–90

    Article  PubMed  CAS  Google Scholar 

  7. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408–15

    Article  PubMed  CAS  Google Scholar 

  8. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 56. London: BMJ Publishing Group Ltd and RPS Publishing, 2008 Sep

  9. Candoni A, Mestroni R, Damiani D, et al. Caspofungin as first line therapy of pulmonary invasive fungal infection in 32 immunocompromised patients with hematological malignancies. Eur J Hematology 2005; 75(3): 227–33

    Article  CAS  Google Scholar 

  10. Denning DW, Marr KA, Lau WM, et al. Micafungin alone or in combination with other systemic antifungal agents for the treatment of acute invasive aspergillosis. J Infect 2006; 53(5): 337–49

    Article  PubMed  Google Scholar 

  11. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based pre-emptive antifungal therapy in neutropenic patients at high risk for invasive fungal infections: a prospective feasibility study. Clin Infect Dis 2005; 41(9): 1242–50

    Article  PubMed  CAS  Google Scholar 

  12. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Inf Dis 2005; 5(10): 609–22

    Article  CAS  Google Scholar 

  13. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44(3): 373–9

    Article  PubMed  Google Scholar 

  14. Greene R. Radiology of fungal infections in the immunocompromised patient. In: Wingard JR, Anaisse EJ, editors. Fungal infections in the immunocompromised patient. Boca Raton (FL): Taylor & Francis Group LLC, 2005: 407–8(B)

    Google Scholar 

  15. Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41(10): 1448–52

    Article  PubMed  CAS  Google Scholar 

  16. Gubbins PO, Anaissie E. Overview of antifungal agents. Inf Dis Special Edition 2007; 10: 58–65

    Google Scholar 

  17. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro crossresistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51(6): 1897–904

    Article  PubMed  CAS  Google Scholar 

  18. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007 Apr 5; 356(14): 1481–3

    Article  PubMed  CAS  Google Scholar 

  19. Habicht JM, Matt P, Passweg JR, et al. Invasive pulmonary fungal infection in hematological patients: is resection effective? Hematology J 2001; 2(4): 250–6

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prophylactic, empirical, pre-emptive and targeted antibacterial therapy all play a role in invasive aspergillosis. Drugs Ther. Perspect 25, 18–22 (2009). https://doi.org/10.2165/0042310-200925010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0042310-200925010-00005

Search

Navigation